Drug Trial Radar · NCT04045496
A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors
Last checked: Nov 20, 2026Latest source record: Dec 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
Sep 26, 2019
Primary completion
Dec 16, 2022
Study completion Dec 16, 2022
Sponsor
- Lead sponsor
- Jacobio Pharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 5, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1, first-in-human, open-label dose-escalation study to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) and assess the DLT of JAB-3312. It is anticipated that approximately 24 subjects will be enrolled in the dose-escalation phase of the study. JAB-3312 will be administered orally once daily (QD) in 21-day treatment cycles.
Conditions
- Non-small Cell Lung Cancer
- Colorectal Cancer
- Pancreatic Ductal Carcinoma
- Esophageal Squamous Cell Carcinoma
- Head and Neck Squamous Cell Carcinoma
- Breast Cancer
- Other Solid Tumors
Interventions
JAB-3312Drug
JAB-3312 will be supplied as 0.25 mg and 1.0 mg capsules.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with dose limiting toxicitiesTime frame: Approximately 2 years
- Find Recommended Phase 2 Dose (RP2D) of JAB-3312Time frame: Approximately 2 years
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
HealthONE Clinic Services Oncology-Hematology
Denver, Colorado
Tennessee Oncology, PLLC
Nashville, Tennessee
The University of Texas M. D. Anderson Cancer Center
Houston, Texas
Washington University School of Medicine
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.